Get the Stockscreener App
82.98
0.69%
0.57
After Hours:
83.15
0.17
+0.20%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Medtronic Plc stock is traded at $82.98, with a volume of 11.03M.
It is up +0.69% in the last 24 hours and down -1.91% over the past month.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
See More
Previous Close:
$82.41
Open:
$82.2
24h Volume:
11.03M
Relative Volume:
1.49
Market Cap:
$106.43B
Revenue:
$33.54B
Net Income/Loss:
$4.66B
P/E Ratio:
22.92
EPS:
3.62
Net Cash Flow:
$5.19B
1W Performance:
+2.85%
1M Performance:
-1.91%
6M Performance:
-4.11%
1Y Performance:
+2.95%
1-Day Range:
$81.51
$83.27
1-Week Range:
$80.71
$83.27
52-Week Range:
$75.96
$96.25
Medtronic Plc Stock (MDT) Company Profile
Name
Medtronic Plc
Sector
Industry
Phone
01135314381700
Address
BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY
Compare MDT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDT
Medtronic Plc
|
82.98 | 103.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
ABT
Abbott Laboratories
|
133.58 | 228.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
105.26 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.64 | 143.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
EW
Edwards Lifesciences Corp
|
78.22 | 43.99B | 5.54B | 4.18B | 623.10M | 7.00 |
Medtronic Plc Stock (MDT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Upgrade | Citigroup | Neutral → Buy |
| Oct-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-21-24 | Reiterated | Oppenheimer | Perform |
| Aug-15-24 | Upgrade | UBS | Sell → Neutral |
| Aug-14-24 | Downgrade | Stifel | Buy → Hold |
| May-30-24 | Initiated | Goldman | Sell |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-24-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-29-23 | Downgrade | UBS | Buy → Sell |
| Jan-09-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-23-22 | Downgrade | Citigroup | Buy → Neutral |
| Nov-23-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Aug-24-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Jun-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-27-22 | Downgrade | Needham | Buy → Hold |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-10-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Dec-15-20 | Upgrade | Goldman | Sell → Neutral |
| Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-08-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Oct-08-20 | Upgrade | Stifel | Hold → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| May-14-20 | Downgrade | DZ Bank | Buy → Hold |
| Mar-30-20 | Downgrade | Needham | Strong Buy → Buy |
| Mar-25-20 | Upgrade | DZ Bank | Hold → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Sell |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-02-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-05-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Feb-04-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Buy |
| Jan-02-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Aug-27-18 | Reiterated | Argus | Buy |
View All
Medtronic Plc Stock (MDT) Latest News
Medtronic (MDT) Sees Increased Bullish Options Activity | MDT St - GuruFocus
Medtronic is telling workers to return to the office more - MassDevice
The Strong Earnings Posted By Medtronic (NYSE:MDT) Are A Good Indication Of The Strength Of The Business - Yahoo Finance
Medtronic (NYSE:MDT) Will Pay A Larger Dividend Than Last Year At $0.71 - simplywall.st
Medtronic plc (MDT): A Bull Case Theory - MSN
Medtronic at Bernstein Conference: Strategic Focus on Growth and Innovation By Investing.com - Investing.com UK
Transcript : Medtronic plc Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 11 - marketscreener.com
Medtronic Splits, Boston Scientific Exits TAVR, J&J Loses Big - Medical Device and Diagnostic industry
Medtronic To Present At Bernstein's Strategic Decisions Conference; Webcast At 11:00 AM ET - Nasdaq
Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.
Medtronic (MDT) Price Target Reduced but Long-Term Buy Rating Maintained | MDT Stock News - GuruFocus
Argus Adjusts Price Target on Medtronic to $105 From $120 - marketscreener.com
Medtronic’s SWOT analysis: medical device giant faces tariffs, sees growth in RDN - Investing.com
Medtronic to spin off its diabetes businessreport - MSN
Atherectomy Devices Market Growth in Future Scope 2025-2032 | - openPR.com
Medtronic: Diabetes Spin-Off Is Near-Term Catalyst; Rating Upgrade (NYSE:MDT) - Seeking Alpha
Medtronic to separate diabetes business following recent struggles - MSN
Medtronic plc (NYSE:MDT) Q4 2025 Earnings Call Transcript - MSN
Medtronic's (NYSE:MDT) Upcoming Dividend Will Be Larger Than Last Year's - Yahoo Finance
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference | MDT Stock News - GuruFocus
Medtronic Leadership to Share Future Growth Strategy at Exclusive Bernstein Conference - Stock Titan
Sector Update: Health Care - marketscreener.com
Medtronic to Split Off Diabetes Unit as Tariffs Hit Earnings - MSN
September 2026 Options Now Available For Medtronic (MDT) - Nasdaq
Redburn Atlantic Adjusts Price Target on Medtronic to $101 From $104 - marketscreener.com
JPMorgan Adjusts Medtronic Price Target to $87 From $95 - marketscreener.com
Jim Cramer on Medtronic (MDT): “I Like This Medical Device Powerhouse” - Insider Monkey
Blood Glucose Monitoring (BGM) Devices Market Report 2025: Hospitals Lead in Blood Glucose Monitoring Device Usage, Home Care Grows Fastest - GlobeNewswire Inc.
Endoscopy Devices Global Market Overview 2021-2030 with Forecasts 2024-2030 - GlobeNewswire Inc.
Medtronic Projects $350M Tariff Hit - Medical Device and Diagnostic industry
Medtronic to separate diabetes business into standalone company - MSN
Medtronic Announces Separation From Diabetes Business, CEO Says it’s “In a Really Good Spot” - Insider Monkey
Medtronic has new Cardiovascular, CST leaders after longtime exec departs - MassDevice
Medtronic (MDT) Plans to Spin Off Diabetes Business - GuruFocus
TD Cowen Keeps a Buy on Medtronic (MDT) After Better Growth in Q4 - Insider Monkey
Medtronic PLC stock underperforms Thursday when compared to competitors - MarketWatch
Abbott vs. Medtronic: Which Dividend-Paying MedTech Stock is Better? - Yahoo Finance
Medtronic PLC (MDT) Stock Price Down 3.66% on May 22 - GuruFocus
Medtronic to separate diabetes business, WSJ reports - MSN
MDT: RBC Capital Lowers Price Target for Medtronic | MDT Stock N - GuruFocus
Medtronic (MDT) Stock Price Target Lowered by Mizuho Analyst | M - GuruFocus
Medtronic inks expanded distro deal for multi-parameter wearable vital sign monitor - MassDevice
Medtronic's Strong Q4 Performance Sets The Stage For Future Growth - Finimize
Medtronic (MDT) Price Target Lowered by Baird Analyst | MDT Stoc - GuruFocus
Medtronic (MDT) Price Target Lowered by Baird Analyst | MDT Stock News - GuruFocus
Medtronic Cardiovascular Strength Drives Fiscal Q4 Beat, RBC Says - marketscreener.com
Why Medtronic plans to spin out its diabetes business - MedTech Dive
July 3rd Options Now Available For Medtronic (MDT) - Nasdaq
Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon - MassDevice
Medtronic (MDT) Price Target Lowered by RBC Capital Amid Growth Investments | MDT Stock News - GuruFocus
Truist Adjusts Price Target on Medtronic to $92 From $90, Maintains Hold Rating - marketscreener.com
Medtronic Plc Stock (MDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):